SCHEMBL8250752

SCHEMBL8250752

COc1cc(F)c(N2CCNCC2)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 4/20 0.54
HTR3A P46098 5/20 0.46
HTR3E A5X5Y0 4/20 0.46
HTR3B O95264 4/20 0.46
HTR3D Q70Z44 4/20 0.46
HTR3C Q8WXA8 4/20 0.46
SIGMAR1 Q99720 2/20 0.46
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
DRD2 P14416 1/20 0.44
CYP2C19 P33261 1/20 0.44
DRD3 P35462 1/20 0.44
HTR6 P50406 1/20 0.44
HTR1A P08908 2/20 0.43
MAPT P10636 1/20 0.43
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
ABCB1 P08183 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14922725 0.90 ADRB1 (0.61) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL14922246 0.86 ADRB1 (0.45) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL25690058 0.81 ADRB1 (0.41) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL25678130 0.81 ADRB1 (0.44) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL31651649 0.76 HTR3A (0.57) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL9523382 0.76 HTR3A (0.57) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL2117991 0.75 HTR3A (0.63) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL28511352 0.73 CHRNB2 (0.53) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL2768723 0.73 HTR3A (0.69) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL17432215 0.73 ALDH1A1 (0.46) ADRB1HTR3AHTR3EHTR3BHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 ADRB1 34/4885HTR3A 7/4885HTR3E 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.